Founded in Shenzhen in 2021, Jingrui Medical operates R&D and manufacturing centers in Hong Kong and Chengdu, with a focus on MRI-compatible medical equipment and comprehensive solutions for complex electromagnetic environments. The company has recently closed a Pre-A financing round totaling tens of millions of yuan, led by Taipu Life Science Investment. These proceeds will be allocated toward core technology R&D, production capacity expansion, and clinical validation of key application scenarios, accelerating large-scale manufacturing and clinical adoption of products built on its proprietary anti-magnetic technology platform, while advancing the localization of high-end medical devices. The core team brings deep industry expertise and a global perspective. In collaboration with the National High Magnetic Field Center, the company has conducted four years of research to develop a four-tier technical architecture and establish a medical electromagnetic compatibility and high anti-magnetic technology platform. Its flagship product operates reliably in 3.0T magnetic field environments, filling a critical supply gap in domestically produced high-end anti-magnetic monitoring equipment. The company has built a collaborative innovation framework to drive clinical validation, and its interdisciplinary medicine-engineering industry-academia-research project has been designated a key project under the provincial science and technology plan. Jingrui Medical is also pursuing regulatory approvals and channel development in ASEAN and Belt and Road partner markets. Looking ahead, the company will continue to iterate its technologies and scale production capacity around core scenarios, progressively expanding into other precision medical applications in complex electromagnetic environments, and promoting the independent controllability and clinical adoption of high-end medical equipment.